Company intelligence / Profile preview
Sinotau Pharmaceutical Group
Beijing, Chinasinotau.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sinotau has successfully commercialized Florbetaben F 18 injection (Neuraceq®/欧韦宁®), the first amyloid PET tracer approved in China for Alzheimer's disease diagnosis. The company has over 20 novel products in different development stages, including Phase 3 trials for Florquinitau F18 for mild cognitive disorders and Phase 2/3 trials for Lutetium Dotatate LU-177 for neuroendocrine tumors.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Diagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsSmall molecule drugsPeptide Conjugate Radionuclide
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
03
Partnerships
Blue Earth Diagnostics LtdLife Molecular ImagingIsotopia Molecular ImagingMeilleur (joint venture)Lantheus
Beyond the preview
Go deeper on Sinotau Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinotau Pharmaceutical Group.